
Privacy notice | Accessibility statement | Terms and conditions | Login | Contact |
UK data driving real-world evidence
Bibliography
Research using CPRD data has informed drug safety guidance and clinical practice and resulted in over 2,700 peer-reviewed publications. The CPRD bibliography is updated on a monthly basis (last updated 6 April 2021) and papers are listed below and in the PDF below.
If you have published papers using CPRD data which are not included in this list, please contact us at enquiries@cprd.com so that we can update the bibliography.
Download:
(PDF, 5MB, 226 pages)This work uses data provided by patients and collected by the NHS as part of their care and support. CPRD encourages researchers to use this citation in all publications using CPRD data. Find out more about acknowledging the use of patient data at the Understanding Patient Data website.
Export 102 results:
[ Author
Filters: First Letter Of Last Name is V [Clear All Filters]
“Do hospitalisations for ambulatory care sensitive conditions reflect low access to primary care? An observational cohort study of primary care usage prior to hospitalisation”, BMJ Open, vol. 7, p. e015704, 2017.
, “Real-world effectiveness evaluation of budesonide/formoterol Spiromax for the management of asthma and chronic obstructive pulmonary disease in the UK”, BMJ Open, vol. 8, p. e022051, 2018.
, “Healthcare resource utilization and costs associated with incremental systemic corticosteroid exposure in asthma”, Allergy, vol. 74, pp. 273-283, 2019.
, “Evaluation of exacerbations and blood eosinophils in UK and US COPD populations”, Respir Res, vol. 20, p. 178, 2019.
, “Resource Utilization Among Glaucoma Patients in the UK Treated with Beta-Blocker and Non-Beta-Blocker Adjunctive Therapy: A Retrospective Cohort Analysis”, Adv Ther, vol. 34, pp. 1695-1706, 2017.
, “The association between glucose-lowering drug use and mortality among breast cancer patients with type 2 diabetes”, Breast Cancer Res Treat, vol. 150, pp. 427-37, 2015.
, “Resource use and costs associated with coeliac disease before and after diagnosis in 3,646 cases: results of a UK primary care database analysis”, PLoS One, vol. 7, p. e41308, 2012.
, “Use of hormone replacement therapy and risk of breast cancer: nested case-control studies using the QResearch and CPRD databases”, Bmj, vol. 371, p. m3873, 2020.
, “Risks and benefits of direct oral anticoagulants versus warfarin in a real world setting: cohort study in primary care”, Bmj, vol. 362, p. k2505, 2018.
, “Patients who discontinued statin treatment: a protocol for cohort study using primary care data”, BMJ Open, vol. 5, p. e008701, 2015.
, “Use of combined oral contraceptives and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD databases”, Bmj, vol. 350, p. h2135, 2015.
, “Exposure to combined oral contraceptives and risk of venous thromboembolism: a protocol for nested case-control studies using the QResearch and the CPRD databases”, BMJ Open, vol. 4, p. e004499, 2014.
, “Exposure to bisphosphonates and risk of common non-gastrointestinal cancers: series of nested case-control studies using two primary-care databases”, Br J Cancer, vol. 109, pp. 795-806, 2013.
, “Exposure to bisphosphonates and risk of gastrointestinal cancers: series of nested case-control studies with QResearch and CPRD data”, Bmj, vol. 346, p. f114, 2013.
, “Use of hormone replacement therapy and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD databases”, Bmj, vol. 364, p. k4810, 2019.
, “Evolution of primary care databases in UK: a scientometric analysis of research output”, BMJ Open, vol. 6, p. e012785, 2016.
, “Estimating the Burden of Medically Attended Norovirus Gastroenteritis: Modeling Linked Primary Care and Hospitalization Datasets”, J Infect Dis, vol. 216, pp. 957-965, 2017.
, “Gender inequality in acute gastro-enteritis rates in England.”, Value in Health, vol. 20, p. A781, 2017.
, “High risk of drug-induced microscopic colitis with concomitant use of NSAIDs and proton pump inhibitors”, Aliment Pharmacol Ther, vol. 43, pp. 1004-13, 2016.
, “Difference in risks of allergic reaction to sulfonamide drugs based on chemical structure”, Ann Pharmacother, vol. 40, pp. 1040-6, 2006.
, “Development of processes allowing near real-time refinement and validation of triage tools during the early stage of an outbreak in readiness for surge: the FLU-CATs Study”, Health Technol Assess, vol. 19, pp. 1-132, 2015.
, “Cohort study of preoperative blood pressure and risk of 30-day mortality after elective non-cardiac surgery”, Br J Anaesth, vol. 119, pp. 65-77, 2017.
, “Effects of five preoperative cardiovascular drugs on mortality after coronary artery bypass surgery: A retrospective analysis of an observational study of 16, 192 patients”, Eur J Anaesthesiol, vol. 33, pp. 49-57, 2016.
, “Preoperative chronic beta-blocker prescription in elderly patients as a risk factor for postoperative mortality stratified by preoperative blood pressure: a cohort study”, Br J Anaesth, 2019.
, “Estimating the health-care costs of children born to pregnant smokers in England: cohort study using primary and secondary health-care data”, Addiction, vol. 113, pp. 1305-1316, 2018.
, “Association between glycemic control and risk of fracture in diabetic patients: A nested case-control study”, J Clin Endocrinol Metab, 2019.
, “Risk of venous thromboembolism with cyproterone or levonorgestrel contraceptives”, Lancet, vol. 358, pp. 1427-9, 2001.
, “Antidepressant use during early pregnancy and the risk of congenital anomalies”, Pharmacotherapy, vol. 33, pp. 693-700, 2013.
, “Antihypertensive drugs and the risk of congenital anomalies”, Pharmacotherapy, vol. 33, pp. 476-82, 2013.
, “Asthma drugs and the risk of congenital anomalies”, Pharmacotherapy, vol. 33, pp. 363-8, 2013.
, “Risk of idiopathic venous thromboembolism in users of progestagens alone”, Lancet, vol. 354, pp. 1610-1, 1999.
, “The risk of venous thromboembolism in users of postcoital contraceptive pills”, Contraception, vol. 59, pp. 79-83, 1999.
, “An increased risk of urinary tract infection precedes development of primary biliary cirrhosis”, BMC Gastroenterol, vol. 11, p. 95, 2011.
, “Primary biliary cirrhosis does not increase the risk of UTIs following diagnosis compared to other chronic liver diseases?”, Liver Int, vol. 33, pp. 384-8, 2013.
, “Relative cost effectiveness of Depo-Provera, Implanon, and Mirena in reversible long-term hormonal contraception in the UK”, Pharmacoeconomics, vol. 22, pp. 1141-51, 2004.
, “Improving the Identification of Out-of-Hospital Sudden Cardiac Deaths in a General Practice Research Database”, Drugs Real World Outcomes, vol. 3, pp. 353-358, 2016.
, “Hormone replacement therapy and incidence of acute myocardial infarction. A population-based nested case-control study”, Circulation, vol. 101, pp. 2572-8, 2000.
, “Hemoglobin mRNA Changes in the Frontal Cortex of Patients with Neurodegenerative Diseases”, Front Neurosci, vol. 12, p. 8, 2018.
, “Association Between Urinary Tract Infections and Antipsychotic Drug Use in Older Adults”, J Clin Psychopharmacol, vol. 38, pp. 296-301, 2018.
, “Upper gastrointestinal adverse events and cyclical etidronate”, Am J Med, vol. 103, pp. 462-7, 1997.
, “Rates of hypoglycemia in users of sulfonylureas”, J Clin Epidemiol, vol. 50, pp. 735-41, 1997.
, “A comparison of cost effectiveness using data from randomized trials or actual clinical practice: selective cox-2 inhibitors as an example”, PLoS Med, vol. 6, p. e1000194, 2009.
, “Study of adverse outcomes in women using testosterone therapy”, Maturitas, vol. 62, pp. 76-80, 2009.
, “Individual fracture risk and the cost-effectiveness of bisphosphonates in patients using oral glucocorticoids”, Rheumatology (Oxford), vol. 46, pp. 460-6, 2007.
, “Individualizing the risks and benefits of postmenopausal hormone therapy”, Menopause, vol. 15, pp. 374-81, 2008.
, “Does the varied use of NSAIDs explain the differences in the risk of myocardial infarction?”, J Intern Med, vol. 264, pp. 481-92, 2008.
, “Evaluating drug toxicity signals: is a hierarchical classification of evidence useful or a hindrance?”, Pharmacoepidemiol Drug Saf, vol. 17, pp. 475-84, 2008.
, “What is the harm-benefit ratio of Cox-2 inhibitors?”, Int J Epidemiol, vol. 37, pp. 405-13, 2008.
, “Does a fracture at one site predict later fractures at other sites? A British cohort study”, Osteoporos Int, vol. 13, pp. 624-9, 2002.
, “Utility of medical and drug history in fracture risk prediction among men and women”, Bone, vol. 31, pp. 508-14, 2002.
,